Here is the design of a clinical trial:

Official Title: A Phase II Study of Primary Chemotherapy, Stereotactic Body Radiation Therapy, and Intraoperative Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

Included conditions:
- Borderline Resectable Pancreatic Cancer

Study Armgroups:
- {'label': 'IORT group', 'type': 'EXPERIMENTAL', 'description': 'Intraoperative administration of 10 to 20 Gy after surgery or as an "in situ" treatment in case resection will not be performed', 'interventionNames': ['Radiation: Intraoperative radiotherapy']}

Interventions:
- {'type': 'RADIATION', 'name': 'Intraoperative radiotherapy', 'description': 'IORT will be delivered as follows:\n\n1. Radical resection --\\> delivery of 10-15 Gy to the tumor bed\n2. Non radical resection --\\> delivery of 15-20 Gy to the tumor "in situ"', 'armGroupLabels': ['IORT group']}

Primary Outcomes:
- {'measure': 'Disease-specific survival', 'timeFrame': '36 months'}

Please estimate the sample size based on the assumption: 
Accrual time: 36 months, Follow-up time: 36 months, Power: 0.90, Significance level (alpha): 0.5, Non-parametric estimate of survival distribution.
Sample size calculation
          The estimate of accrual was calculated hypothesizing that total neoadjuvant therapy with FOLFIRINOX + SBRT + IORT will improve the 3-year survival rate up to 37% in comparison with cohort-level institutional data (patients <â75âyears with BRPC undergoing neoadjuvant FOLFIRINOX, 3-year survival of 23.7%) Accrual time was set at 36âmonths and follow-up at 36âmonths. At a power of 0.90, and alpha of 0.5 a sample size of 100 patients was calculated assuming a non-parametric estimate of survival distribution. The SWOG Cancer Research and Biostatistics one-arm trial with time-to-event data sample size calculator was employed [26].